These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15793560)

  • 1. Methods of analysis for chemicals that disrupt cellular signaling pathways: risk assessment for potential endocrine disruptors.
    Umezawa Y; Ozawa T; Sato M; Inadera H; Kaneko S; Kunimoto M; Hashimoto S
    Environ Sci; 2005; 12(1):49-64. PubMed ID: 15793560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically encoded optical probes for imaging cellular signaling pathways.
    Umezawa Y
    Biosens Bioelectron; 2005 Jun; 20(12):2504-11. PubMed ID: 15854822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening of endocrine disrupting chemicals with MELN cells, an ER-transactivation assay combined with cytotoxicity assessment.
    Berckmans P; Leppens H; Vangenechten C; Witters H
    Toxicol In Vitro; 2007 Oct; 21(7):1262-7. PubMed ID: 17572059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensing estrogen's many pathways.
    Weatherman RV
    ACS Chem Biol; 2008 Jun; 3(6):338-40. PubMed ID: 18570353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
    Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
    Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes and pathways.
    Yang F; Foekens JA; Yu J; Sieuwerts AM; Timmermans M; Klijn JG; Atkins D; Wang Y; Jiang Y
    Oncogene; 2006 Mar; 25(9):1413-9. PubMed ID: 16261164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
    Massarweh S; Schiff R
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted salmon gene array (SalArray): a toxicogenomic tool for gene expression profiling of interactions between estrogen and aryl hydrocarbon receptor signalling pathways.
    Mortensen AS; Arukwe A
    Chem Res Toxicol; 2007 Mar; 20(3):474-88. PubMed ID: 17291011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
    Zhang H; Stephens LC; Kumar R
    Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologic levels of 2-methoxyestradiol interfere with nongenomic signaling of 17beta-estradiol in human breast cancer cells.
    Vijayanathan V; Venkiteswaran S; Nair SK; Verma A; Thomas TJ; Zhu BT; Thomas T
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2038-48. PubMed ID: 16609013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.
    Gururaj AE; Rayala SK; Vadlamudi RK; Kumar R
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1001s-1007s. PubMed ID: 16467116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer.
    Yamaguchi Y; Takei H; Suemasu K; Kobayashi Y; Kurosumi M; Harada N; Hayashi S
    Cancer Res; 2005 Jun; 65(11):4653-62. PubMed ID: 15930283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
    Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
    Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
    Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
    Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A genetically encoded indicator for assaying bioactive chemicals that induce nuclear transport of glucocorticoid receptor.
    Kim SB; Ozawa T; Umezawa Y
    Anal Biochem; 2005 Dec; 347(2):213-20. PubMed ID: 16269125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steroidogenic acute regulatory (StAR) protein and cholesterol side-chain cleavage (P450scc)-regulated steroidogenesis as an organ-specific molecular and cellular target for endocrine disrupting chemicals in fish.
    Arukwe A
    Cell Biol Toxicol; 2008 Dec; 24(6):527-40. PubMed ID: 18398688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health risk assessment procedures for endocrine disrupting compounds within different regulatory frameworks in the European Union.
    Beronius A; Rudén C; Hanberg A; Håkansson H
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):111-22. PubMed ID: 19500631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of endocrine disruptor chemicals in gynaecology.
    Caserta D; Maranghi L; Mantovani A; Marci R; Maranghi F; Moscarini M
    Hum Reprod Update; 2008; 14(1):59-72. PubMed ID: 18070835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid hormone receptor signaling in tumorigenesis.
    Singh RR; Kumar R
    J Cell Biochem; 2005 Oct; 96(3):490-505. PubMed ID: 16092128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interference of pollutants with PPARs: endocrine disruption meets metabolism.
    Casals-Casas C; Feige JN; Desvergne B
    Int J Obes (Lond); 2008 Dec; 32 Suppl 6():S53-61. PubMed ID: 19079281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.